CN109652344A - Bacterial strain and its application and vaccine and preparation method thereof - Google Patents
Bacterial strain and its application and vaccine and preparation method thereof Download PDFInfo
- Publication number
- CN109652344A CN109652344A CN201910118327.1A CN201910118327A CN109652344A CN 109652344 A CN109652344 A CN 109652344A CN 201910118327 A CN201910118327 A CN 201910118327A CN 109652344 A CN109652344 A CN 109652344A
- Authority
- CN
- China
- Prior art keywords
- mink
- plants
- type
- vaccine
- parvovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 77
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 241000772415 Neovison vison Species 0.000 claims abstract description 157
- 241000894006 Bacteria Species 0.000 claims abstract description 61
- 241000125945 Protoparvovirus Species 0.000 claims abstract description 54
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 38
- 230000002008 hemorrhagic effect Effects 0.000 claims abstract description 38
- 229940031551 inactivated vaccine Drugs 0.000 claims abstract description 32
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 31
- 208000004232 Enteritis Diseases 0.000 claims abstract description 25
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 40
- 239000001963 growth medium Substances 0.000 claims description 31
- 238000011081 inoculation Methods 0.000 claims description 24
- 239000011265 semifinished product Substances 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 230000002779 inactivation Effects 0.000 claims description 20
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004202 carbamide Substances 0.000 claims description 14
- 238000003306 harvesting Methods 0.000 claims description 14
- 239000007836 KH2PO4 Substances 0.000 claims description 10
- 241001508687 Mustela erminea Species 0.000 claims description 10
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 10
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000001509 sodium citrate Substances 0.000 claims description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 9
- 239000000337 buffer salt Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 2
- 239000005723 virus inoculator Substances 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 36
- 238000011218 seed culture Methods 0.000 abstract description 16
- 230000036039 immunity Effects 0.000 abstract description 8
- 230000003053 immunization Effects 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 238000002649 immunization Methods 0.000 abstract description 4
- 241000701931 Canine parvovirus Species 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 101150051135 Mink1 gene Proteins 0.000 description 142
- 241000196324 Embryophyta Species 0.000 description 90
- 238000000855 fermentation Methods 0.000 description 22
- 230000004151 fermentation Effects 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 239000002574 poison Substances 0.000 description 15
- 231100000614 poison Toxicity 0.000 description 15
- 230000036541 health Effects 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 239000001888 Peptone Substances 0.000 description 8
- 108010080698 Peptones Proteins 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 235000019319 peptone Nutrition 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 238000009395 breeding Methods 0.000 description 7
- 230000001488 breeding effect Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000282339 Mustela Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 230000002633 protecting effect Effects 0.000 description 6
- 230000000405 serological effect Effects 0.000 description 6
- 230000001018 virulence Effects 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 238000009781 safety test method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 231100000041 toxicology testing Toxicity 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010015856 Extrasystoles Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009313 farming Methods 0.000 description 4
- 238000005096 rolling process Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 239000002518 antifoaming agent Substances 0.000 description 3
- 238000004500 asepsis Methods 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 208000002648 Mink Viral Enteritis Diseases 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000001058 brown pigment Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 101000730040 Klebsiella pneumoniae Arylsulfatase Proteins 0.000 description 1
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 208000033398 Pneumonia pseudomonas aeruginosa Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000012271 agricultural production Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001056 green pigment Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/38—Pseudomonas
- C12R2001/385—Pseudomonas aeruginosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to field of biotechnology, in particular to bacterial strain and its application and vaccine and preparation method thereof.The present invention provides a kind of Mink Parvovirus Enteritis, hemorrhagic pneumonia bivalent inactivated vaccine and its preparation process, (bacterium) seed culture of viruses of the vaccine is DL15 plants of MEVB plants of the Mink Parvovirus strain and mink pseudomonas aeruginosa G type of China's prevalence, JL08 plants of Type B, WD01 plants of c-type, WF05 plants of I type, DL03 plants of F type, as being mixed in proportion with after formalin-inactivated respectively after the Canine Parvovirus Enteritis of antigen and pseudomonas aeruginosa strains culture, aluminium hydroxide gel is proportionally added into be formulated, the vaccine immunity phase is 6 months, 80% or more immune protective rate, it can be used to prevent Mink Parvovirus Enteritis and mink hemorrhagic pneumonia simultaneously, reduce the immunization amount and mink stress reaction of raiser, market application prospect is preferable.
Description
The application be the applying date be 2016.02.17, entitled " bacterial strain and its application and vaccine and its preparation side
Method ", application No. is the divisional applications of the invention of 201610089542.X.
Technical field
The present invention relates to field of biotechnology, in particular to bacterial strain and its application and vaccine and preparation method thereof.
Background technique
Fur-bearing animal refers mainly to the animal that product is fur coat raw material processed.With the development of economy, the improvement of people's living standards
With the continuous growth of demand, China fur industry shows powerful development trend.China's fur animal farming is concentrated mainly on
The ground such as Shandong, Hebei, Liaoning and Heilungkiang, the kind of cultivation mainly have mink, racoon dog, fox, a beaver rabbit, produce per year standard mink skin 6,000,000,
Raw fox skin 2,000,000, wherein raw fox skin accounts for the 35% of Gross World Product, and standard mink skin accounts for the 12% of Gross World Product.By for many years
Development and accumulation, Fur Animal Feeding has become a strong industry, and it is raw that China has become maximum fur product in the world
State and exported country are produced, its development is not only that a large amount of foreign exchanges have been earned by country, has also directly driven the adjustment of the structure of agricultural production, has promoted
Increasing peasant income, some areas even have become the mainstay industry of regional economy, to pushing agriculture, rural areas and farmers economic developments to play
Important role.
Mink hemorrhagic pneumonia is a kind of acute infectious disease for causing mink by pseudomonas aeruginosa, mostly occurs in autumn temperature
Warm current is wet, is clinical special disease with cough, expiratory dyspnea, haematemesis, nosebleed, with lung large-area hemorrhage, pulmonary hepatization, pulmonary edema is
Major lesions feature, disease incidence 20%-50%, the death rate 100%.Sick ermine morbidity is anxious, dead fast, often breaks out in region
Property it is popular.In recent years since mink farming scale and intensive degree significantly improve, the disease incidence of mink hemorrhagic pneumonia is significant
Rise, which deepens year by year, it has also become endangers one of the Infectious Diseases of China's mink farming.
Drug resistance problems are also easy to produce in view of the characteristics of incidence of the disease and the bacterium, it is often highly difficult to cure the disease with medicine, goes out
Live vaccine is the most effectual way for preventing the disease, is prepared into polyvalent inactivation epidemic disease after the bacterial strain of serotype popular in mink is inactivated
Seedling can effectively prevent the disease caused by similar serological type strain, and " biological characteristics of mink pseudomonas aeruginosa separation strains compare
Analysis and serotype investigation " (Bai Xue, Chai Xiuli, Yan Xijun, Gao Han, Zhang Hailing, Zhao Jianjun, Zhang Lei, Shao Xiqun, Luo Guoliang, king
Long phoenix), " mink hemorrhagic pneumonia bivalent inactivated vaccine and preparation method thereof " (patent No.: ZL201010203879.1, Yan Xi
Army, Bai Xue, Chai Xiuli, Luo Guoliang, Zhao Jianjun, Zhang Hailing, Shao Xiqun, Zhang Lei, Gao Han) it discloses China and causes mink bleeding
Property pneumonia pseudomonas aeruginosa predominant serotypes be G type and Type B, and utilize this 2 kinds of serological type strain DL15 (national strains
Deposit number CGMCC NO.3811) and JL08 (national culture presevation CGMCC NO.3812) having developed can be used for prevents mink
The bivalent inactivated vaccine of hemorrhagic pneumonia, the product in 2011 obtain the clinical test official written reply of the Ministry of Agriculture, and carry out simultaneously
Clinical application.Obtain within 2016 national novel chiral synthon certificate (three classes).
Caused by mink viral enteritis is mink enteritis parvovirus (Minkenteritis parvovirus, MEV)
Using violent diarrhea as the acute strong, highly contagious disease of Major Clinical spy's disease, the death rate is up to 80% or more, the disease
Worldwide it is widely current, under field conditions (factors), the equal infectious of the ermine of different cultivars and all ages and classes, but the sense of young ermine
Metachromia is extremely strong, and with the development of special livestock breeding, viral enteritis, which has become, endangers one of three big epidemic diseases of mink farming, gives
Mink breeding industry brings huge economic loss, and nineteen forty-seven is found earliest as Canadian scholar Schofield and reported caused by MEV
Disease.Jiang Tingxiu in 1981 etc. first reported China and mink viral enteritis occur, and hereafter the disease gradually spreads the whole nation, provisions
Ermine industry brings huge economic loss.My unit Wu Wei etc. with monoclonal antibody to the mink enteritis parvovirus of isolated in China into
Row system pattern determines that China's mink enteritis parvovirus is mainly caused by Type B parvovirus, selects virulence on this basis
Stablize, good Strain MEVB plants of immunogenicity, and develop Mink Parvovirus inactivated vaccine, obtains country within 2010
Novel chiral synthon certificate (three classes), and apply on the market rapidly.Control the disease preferably.
The country does not have the bigeminy vaccine of Mink Parvovirus Enteritis, mink hemorrhagic pneumonia also at present, in the market also without
This kind of Combined vaccine uses.And using single seedling need that mink is repeatedly immunized, immunizing dose is big, and immune programme is cumbersome, increases
Human and material resources and financial resources cost, while also easily causing the stress reaction of mink.
This project develops that " needle is anti-on the basis of studying successfully Mink Parvovirus Enteritis and mink hemorrhagic pneumonia
Two disease " Mink Parvovirus Enteritis and hemorrhagic pneumonia bivalent inactivated vaccine, technically captured connection seedling in two kinds at
The problem of point parvovirus and the antigenic component of pseudomonas aeruginosa interfere with each other, vaccine contg is with when production technology.Originally it grinds
Study carefully on the basis of mink hemorrhagic pneumonia bivalent inactivated vaccine is developed, newly joined the prevalence occurred in recent years in vaccine strain
Strain I type, c-type and F type, are prepared as five bivalent inactivated vaccine of mink hemorrhagic pneumonia (G type, Type B, I type, c-type and F type), can be right
The prevalence of the new serological type strain of mink hemorrhagic pneumonia plays good prevention effect, can solve domestic original vaccine to this
Disease can only provide the problem of part protection, the more effective generation for preventing mink hemorrhagic pneumonia.By being ground to bigeminy vaccine
System and key technology innovation, develop a kind of efficient, Small side effects, the feasible Combined vaccine of marketing, it is immune to solve single seedling
Challenge in program meets industry and the urgent need of raiser, has a vast market application prospect.
The prior art is that this two Pseudomonas aeruginosa strains PYG culture medium is increased bacterium training by the culture technique ventilated with rolling bottle
It supports, receives bacterium after 37 DEG C of 180r/m shaking table culture 12h, 40 are respectively reached with the bacterium amount that bacterial plate counts method measures two plants of bacterium ×
108CFU/ml is mixed G type bacterial strain and Type B bacterial strain in the ratio of 2:1；(1) with final concentration of 0.15% formalin to copper
Green pseudomonad is inactivated, and for 24 hours in 37 DEG C of inactivations, is during which shaken 2~3 times；(2) bacterium solution after inactivation is added into 20% ratio
Mink pseudomonas aeruginosa multivalent inactivated vaccine can be obtained in aluminium hydroxide gel after mixing.Original culture medium: PYG culture medium
Composition: peptone 2%, glucose 1%, sodium chloride 0.5%, yeast powder 0.3% are prepared with deionized water, have been matched and have been adjusted pH value 7.2
~7.4,116 DEG C of 30min.But rolling bottle ventilation culture thallus is used, inoculative proportion is 3%~4%, ventilation 12~15h of culture,
Since the rolling bottle production technology of vaccine falls behind, rolling bottle number is more to be easy to pollute when connecing bacterium, and incubation time is long, and production bacterium number is few,
Between 20~4,000,000,000 CFU/ml, it is only applicable to the small lot production of vaccine development early period.
Select 3 kinds of current Major Epidemic serotype G, Type B and Klebsiella Pneumoniae K1 type bacterial strain systems of pseudomonas aeruginosa
For at inactivated vaccine.It has been immunized using 10% inactivation Klebsiella Pneumoniae as the vaccine of adjuvant, protective rate 83%；Be immunized with
10%Al (OH)3The vaccine of adjuvant, protective rate 71%；And as blank control group, the 6th group for only having injected physiological saline is small
The survival rate of mouse is 33%.Relative to traditional Al (OH)3Adjuvant, Klebsiella Pneumoniae itself can be used as vaccine composition, protect
Body is protected from the infection of the pathogen, while having good immunoregulatory activity concurrently again, strengthens body to P. aeruginosa
The immune response of bacterium produces higher antibody level and provides better immunoprotection, and veterinary clinic has certain answer
With value.
Vaccine strain serotype used in the mink hemorrhagic pneumonia of above several developments mainly includes 2 kinds or 3 kinds, i.e. G
Type, Type B or G type, c-type, I type, according to our unit carry out mink hemorrhagic pneumonia epidemiological survey, 2010 to 2015
Newly there is F type, I type and c-type in the popular serotype in year, and since the cross protection rate between various popular serotypes is low, greatly
About 20%-30%.It is therefore necessary to all possible popular serotype is added.
Summary of the invention
In view of this, the present invention provides bacterial strain and its applications and vaccine and preparation method thereof.The vaccine immunity phase is
6 months, 80% or more immune protective rate can be used to prevent simultaneously Mink Parvovirus Enteritis and mink hemorrhagic pneumonia,
Immunization amount and mink stress reaction, the market application prospect for reducing raiser are preferable.
In order to achieve the above-mentioned object of the invention, the present invention the following technical schemes are provided:
The present invention also provides a kind of P. aeruginosa bacterial strain, deposit number is CGMCC No.11990.
It is CGMCC No.11988, CGMCC No.11990 and CGMCC No.11989 the present invention also provides deposit number
P. aeruginosa bacterial strain preparation mink hemorrhagic pneumonia vaccine in application.
It is CGMCC No.11988, CGMCC No.11990 and CGMCC No.11989 the present invention also provides deposit number
P. aeruginosa bacterial strain prepare Mink Parvovirus Enteritis, the application in hemorrhagic pneumonia bivalent inactivated vaccine.
The present invention provides a kind of mink hemorrhagic pneumonia vaccines, be CGMCC No.11988 by deposit number of the present invention,
The P. aeruginosa bacterial strain and DL15 plants of mink pseudomonas aeruginosa G type, B of CGMCC No.11990 and CGMCC No.11989
JL08 plants of type are made.
The present invention also provides a kind of Mink Parvovirus Enteritis, the bivalent inactivated vaccine of hemorrhagic pneumonia, You Benfa
Bright deposit number be CGMCC No.11988, CGMCC No.11990 and CGMCC No.11989 P. aeruginosa bacterial strain and
DL15 plants of mink pseudomonas aeruginosa G type, JL08 plants of Type B and MEVB plants of Mink Parvovirus strain are made.
In some specific embodiments of the invention, the preparation method of bivalent inactivated vaccine includes the following steps:
Step 1: taking deposit number of the present invention is CGMCC No.11988, CGMCC No.11990 and CGMCC No.11989
P. aeruginosa bacterial strain and DL15 plants of mink pseudomonas aeruginosa G type, JL08 plants of Type B be inoculated in culture medium culture respectively after
Pseudomonas aeruginosa pentavalent seedling semi-finished product bacterium solution after inactivation is made after mixing, inactivation；
Step 2: taking MEVB plants of inoculating cells of Mink Parvovirus strain, harvest inactivates obtained parvovirus semi-finished product；
Step 3: taking thin made from pseudomonas aeruginosa pentavalent seedling semi-finished product bacterium solution and step 2 after step 1 inactivation obtained
Small virus semi-finished product are mixed to prepare mixed liquor；
Step 4: mixed liquor made from step 3 being taken to mix with adjuvant.
In some specific embodiments of the invention, preservation of the present invention in the preparation method step 1 of bivalent inactivated vaccine
Number is CGMCC No.11988, the P. aeruginosa bacterial strain and mink copper of CGMCC No.11990 and CGMCC No.11989
Respectively after culture medium culture, the mixed ratio is 1:1:1:1:1 (v/ for DL15 plants of green pseudomonad G type, JL08 plants of Type B
V), the bacterium number of every plant of bacterium is at least 4,000,000,000 CFU/mL after mixing.
In some specific embodiments of the invention, preparation method step 2 parvovirus of bivalent inactivated vaccine half at
The content of parvovirus is 10 in product6.00TCID50。
In some specific embodiments of the invention, step 1 described in the preparation method step 3 of bivalent inactivated vaccine is made
Inactivation after the ratio of parvovirus semi-finished product mixing made from pseudomonas aeruginosa pentavalent seedling semi-finished product bacterium solution and step 2 be 2:
1。
In some specific embodiments of the invention, culture medium described in the preparation method step 1 of bivalent inactivated vaccine
For PYG culture medium, MgSO preferably is added in PYG culture medium4, urea, sodium citrate, vitamin, Na2HPO4Buffer salt or
KH2PO4One of buffer salt is a variety of；
Preferably, culture medium prescription: peptone 3%, glucose 2%, yeast powder 0.3%, sodium chloride 0.5%,
Na2HPO42.5g/L, KH2PO40.83g/L, MgSO40.3g/L, sodium citrate 0.3g/L, urea 2g/L, vitamin liquid 10mL/
L；
Inoculation described in step 1 is according to 3% inoculating strain of PYG culture volume；Described in step 2 inoculation for according to
2% virus inoculation of CRFK cell suspension volume.
In some specific embodiments of the invention, go out described in the preparation method step 1 or step 2 of bivalent inactivated vaccine
It is living to use formalin-inactivated；The dosage of the formaldehyde is the 0.2% of bacterium solution total amount.
Preferably, inactivation described in step 1 or step 2 is to be slowly added to formalin, Bian Jia by the 0.2% of bacterium solution total amount
Side stirring, 36~37 DEG C of stirrings inactivate 24 hours.
In some specific embodiments of the invention, adjuvant described in the preparation method step 4 of bivalent inactivated vaccine is
The mixed proportion of 40% (w/v, in terms of g/mL) aluminium hydroxide gel, mixed liquor made from step 3 and the adjuvant is 6:1.
Specific packet is cultivated in some specific embodiments of the invention, in the preparation method step 1 of bivalent inactivated vaccine
Include following steps:
Step 1: first order seed breeding: take DL15 plants, JL08 plants, WD01 plants, WF05 plants, DL03 plants of bacterial strain freeze-drying lactobacillus it is each
1 unpacking, diluted with sterile saline, respectively be inoculated with PYG agar medium (culture medium prescription: peptone 3%,
Glucose 2%, yeast powder 0.3%, sodium chloride 0.5%, Na2HPO42.5g/L, KH2PO40.83g/L, MgSO40.3g/L, Chinese holly
Rafter acid sodium 0.3g/L, urea 2g/L, vitamin liquid 10mL/L, agar powder 2g/L), 36~37 DEG C are cultivated 18~24 hours, respectively
It selects 5 or more colonies typicals to be mixed in a small amount of PYG fluid nutrient medium, then inoculation PYG agar slant culture-medium is (described respectively
Culture medium prescription: peptone 3%, glucose 2%, yeast powder 0.3%, sodium chloride 0.5%, Na2HPO42.5g/L, KH2PO4
0.83g/L, MgSO40.3g/L, sodium citrate 0.3g/L, urea 2g/L, vitamin liquid 10mL/L, agar powder 2g/L) it is several,
36~37 DEG C are cultivated 18~24 hours, as first order seed.2~8 DEG C of preservations, validity period are no more than 15, and passage is no more than 5
Generation；
Step 2: secondary seed breeding: first order seed being taken to be inoculated with several 5mL PYG fluid nutrient medium (trainings respectively
Support based formulas: peptone 3%, glucose 2%, yeast powder 0.3%, sodium chloride 0.5%, Na2HPO42.5g/L, KH2PO4
0.83g/L, MgSO40.3g/L, sodium citrate 0.3g/L, urea 2g/L, vitamin liquid 10mL/L) in, 36~37 DEG C of shakings 12
Hour, then be inoculated in larger amount of PYG fluid nutrient medium respectively in 3% ratio, 36~37 DEG C shake 12 hours, are purely examined
After qualification, as secondary seed, 2~8 DEG C of preservations are set, should be no more than 4；
Step 3: fermentation seed liquid preparation: the secondary seed is inoculated in fermentation medium, 37~37.5 DEG C of temperature,
Fermented and cultured 7h under the conditions of 100~120r/min of mixing speed, 70~90L/min of charge flow rate, 30~70Kpa of pressure is obtained
Fermentation seed liquid；
Step 4: one grade fermemtation: fermentation seed liquid being inoculated in 3% ratio equipped with 250~300L PYG culture medium (institute
The culture medium prescription stated: peptone 3%, glucose 2%, yeast powder 0.3%, sodium chloride 0.5%, Na2HPO42.5g/L
KH2PO40.83g/L, MgSO40.3g/L, sodium citrate 0.3g/L, urea 2g/L, vitamin liquid 10mL/L) 500L fermentation
Tank, be added defoaming agent GPE, cultivate 6~7h after be separately added into glucose to final concentration of 1% and urea to final concentration 2g/L make
For supplementary carbon source, main control parameters are as follows during fermentation:: 37~37.5 DEG C of tank temperature, 80~110r/min of mixing speed, air inlet
80~120L/min of flow, tank press 30~70Kpa, 12h harvest, through purely after the assay was approved, as semi-finished product bacterium solution, bacterium number are steady
It is scheduled on 25,000,000,000 CFU/mL；
Step 5: second order fermentation: fermentation seed liquid being inoculated in 4% ratio equipped with 500L~600L PYG culture medium (institute
The culture medium prescription stated: peptone 3%, glucose 2%, yeast powder 0.3%, sodium chloride 0.5%, Na2HPO42.5g/L
KH2PO40.83g/L, MgSO40.3g/L, sodium citrate 0.3g/L, urea 2g/L, vitamin liquid 10mL/L) 1000L fermentation
Tank is separately added into glucose to final concentration of 1% and urea to final concentration 2g/L as supplementary carbon source after cultivating 6~7h, is added
Defoaming agent GPE, main control parameters are as follows during fermentation:: 37~37.5 DEG C of tank temperature, 80~100r/min of mixing speed, air inlet
90~136L/min of flow, tank press 30~70Kpa, 12h harvest, through purely after the assay was approved, as semi-finished product bacterium solution, bacterium number can
Stablize in 25,000,000,000 CFU/ml.
In some specific embodiments of the invention, cultivated in the preparation method step 2 of bivalent inactivated vaccine specifically:
Basic seed culture of viruses is diluted with cell maintenance medium, synchronizes and is inoculated in CRFK cell suspension in 2% ratio, sets 37 DEG C of cultures
It 3~4, when typical case CPE occurs in 80% or more cell, can harvest, -20 DEG C of preservations.
In some specific embodiments of the invention, the culture medium and fermentor of pseudomonas aeruginosa provided by the invention
Culture medium is improved on the basis of the original PYG culture medium of culture process (glucose-peptone-yeast powder), passes through addition
MgSO required for bacterial metabolism4, sodium citrate, vitamin hydroful foot high-speed fermentation nutritional need, and pass through addition
Na2HPO4, KH2PO4The stabilization that salt maintains pH value and thallus osmotic pressure is buffered, in addition, supplementing grape in 6~7h of fermented and cultured
Sugar and urea pass through the foundation of 100L, 500L, 1000L fermentor fermentation process step by step, it is determined that the bacterium number of seed liquor, inoculation
Ratio, seed liquor holding time, passage number, fermentation harvest time make bacterium number that can stably reach 25,000,000,000 CFU, than original method
Bacterium number improves 5~10 times.
The present invention newly joined close several on the basis of mink hemorrhagic pneumonia bivalent inactivated vaccine is developed in vaccine strain
Epidemic strain I type, c-type and the F type that year occurs, are prepared as five bivalent inactivated vaccine of mink hemorrhagic pneumonia, can be to mink hemorrhagic
The prevalence of the new serological type strain of pneumonia plays good prevention effect, can solve can only providing the disease for domestic original vaccine
The problem of part is protected, so as to effectively prevent the generation of mink hemorrhagic pneumonia.The vaccine immunity phase is 6 months, is immunized and protects
80% or more shield rate can be used to prevent simultaneously Mink Parvovirus Enteritis and mink hemorrhagic pneumonia, reduce raiser
Immunization amount and mink stress reaction, market application prospect it is preferable.
Biological deposits explanation
Bacterial strain WD01, classification naming: pseudomonas aeruginosa Pseudomonas aeruginosa. was on 01 11st, 2016
It is deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center, address is BeiChen West Road, Chaoyang District, BeiJing City 1
Number institute 3, Institute of Microorganism, Academia Sinica, deposit number are CGMCC No.11988；
Bacterial strain WF05, classification naming: pseudomonas aeruginosa Pseudomonas aeruginosa. was on 01 11st, 2016
It is deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center, address is BeiChen West Road, Chaoyang District, BeiJing City 1
Number institute 3, Institute of Microorganism, Academia Sinica, deposit number are CGMCC No.11990；
Bacterial strain DL03, classification naming: pseudomonas aeruginosa Pseudomonas aeruginosa. was on 01 11st, 2016
It is deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center, address is BeiChen West Road, Chaoyang District, BeiJing City 1
Number institute 3, Institute of Microorganism, Academia Sinica, deposit number are CGMCC No.11989.
Detailed description of the invention
In order to more clearly explain the embodiment of the invention or the technical proposal in the existing technology, to embodiment or will show below
There is attached drawing needed in technical description to be briefly described.
Fig. 1 shows that pseudomonas aeruginosa antibody ELISA immunosorbent adsorption test measurement result after Combined vaccine is immunized in mink；
Fig. 2 shows that parvovirus hemagglutination inhibition antibody measurement result after Combined vaccine is immunized in mink；
Fig. 3 shows that parvovirus neutralizing antibody measurement result after Combined vaccine is immunized in mink.
Specific embodiment
The invention discloses bacterial strain and its application and vaccine and preparation method thereof, those skilled in the art can be used for reference
Present disclosure is suitably modified realization of process parameters.In particular, it should be pointed out that all similar substitutions and modifications are to this field skill
It is it will be apparent that they are considered as being included in the present invention for art personnel.Method of the invention and application by compared with
Good embodiment is described, related personnel obviously can not depart from the content of present invention, in spirit and scope to as described herein
Methods and applications are modified or appropriate changes and combinations, carry out implementation and application the technology of the present invention.
Bacterial strain uses therefor, raw material and reagent are equal in bacterial strain provided by the invention and its application and vaccine and preparation method thereof
It is available on the market.Wherein, the deposit number of bacterial strain DL15 is CGMCC No.3811；The deposit number of bacterial strain JL08 is CGMCC
No.3812；MEVB plants of screening techniques of Strain are see " research of China's mink enteritis parvovirus Major Epidemic type " Wu Wei；Nie
Jin Zhen；Wang Kejian；Cheng Shipeng；Chinese animal doctor's journal, 04 phase in 1996.
Culture medium prescription in specific embodiments of the present invention are as follows: peptone 3%, glucose 2%, yeast powder 0.3%, chlorine
Change sodium 0.5%, Na2HPO42.5g/L, KH2PO40.83g/L, MgSO40.3g/L, sodium citrate 0.3g/L, urea 2g/L, dimension
Raw element liquid 10mL/L.
Below with reference to embodiment, the present invention is further explained:
The preparation of embodiment 1 Mink Parvovirus Enteritis, hemorrhagic pneumonia bivalent inactivated vaccine
1. vaccine bacterium kind standard:
1.1 pseudomonas aeruginosa bacterial standards
1.1.1 form and this bacterium of biochemical characteristic are gram-Negative bacillus.Biochemical characteristic should meet this in systematic bacteriology
The characteristic of bacterium.
1.1.2 cultural character is seeded on PYG agar plate, is cultivated 18~24 hours, is visually observed at 36~37 DEG C,
Bacterium colony is flat wet, and edge is irregular, and generation diffuses marennin or brown pigment in culture medium；It is inoculated with PYG Liquid Culture
In base, 36~37 DEG C are cultivated 18~24 hours, and liquid is uniformly muddy, generate green or brown pigment.
1.1.3 serological characteristic is formed with pseudomonas aeruginosa blood grouping serum, and DL15 plants should be G type, and JL08 plants should be B
Type, WD01 plants should be c-type, WF05 plant and should be I type, DL03 plant and should be F type.
1.1.4 virulence strain DL15 plants, JL08 plants, WD01 plants, WF05 plants, DL03 plants is inoculated with PYG fluid nutrient medium respectively
In 37 DEG C shaken cultivation 12 hours, bacterium solution culture virulence should meet claimed below.
1.1.4.1 DL15 plants, WD01 plants and WF05 plants are with 16~18g mouse 10, every mouse hypodermic inoculation viable bacteria
0.2ml (70,000,000 CFU/0.2ml containing viable bacteria), mouse should be all dead in 48 hours；With 2~10 monthly ages susceptible mink 5 of health
Only, every intratracheal instillation viable bacteria 1ml (200,000,000 CFU/ml containing viable bacteria).Mink should be all dead in 72 hours.
1.1.4.2 JL08 plants and DL03 plant are with 16~18g mouse 10, and every subcutaneous vaccination viable bacteria 0.2ml is (containing viable bacteria
1.2 hundred million CFU/0.2ml), mouse should be all dead in 48 hours；With 2~10 monthly ages health susceptible mink 5, every intratracheal
It instills viable bacteria 1ml (400,000,000 CFU/ml containing viable bacteria).Mink should be all dead in 72 hours.
1.1.5 immunogenicity
1.1.5.1 mouse is divided into 5 groups, every group 10, single bacterium type is subcutaneously injected respectively with 16~18g of weight mouse 50
Vaccine 0.2ml divides 5 groups, every group 10, is respectively subcutaneously injected 70,000,000 CFU/0.2ml's together with control mice 50 after 21 days
The JL08 strain of DL15 plants, WD01 plants or WF05 plants of virulent liquid or 1.2 hundred million CFU/0.2ml or DL03 plants of virulent liquid, it is continuous to see
It examines 7.Control mice should be all dead, and immune mouse should at least protect 8.
1.1.5.2 susceptible mink 25 of 2~10 monthly ages health of mink divides 5 groups, every group 5, distinguishes intramuscular injection list
Bacterial type vaccine 1ml divides 5 groups, every group 5, intratracheally instills 200,000,000 CFU/ml's respectively together with control mink 25 after 21 days
DL15 plants, WD01 plants or WF05 plants or 400,000,000 CFU/ml of JL08 strain or DL03 plants of virulent liquid, are observed continuously 7.Compare mink
Should be all dead, immune mink should at least protect 4.
1.1.6 it is purely checked with PYG culture medium (note 2), it should be pure.
1.1.7 5~10 generation of algebra basic seed.
1.1.8 virulent standard
1.1.8.1 form and biochemical characteristic, cultural character, serological characteristic and the same 1.1.1,1.1.2 of virulence, 1.1.3,
1.1.4。
1.1.8.1 the inspection of PYG culture medium is purely used, it should be pure.
1.1.8.1 5~10 generation of subalgebra is planted.
1.1.9-20 DEG C of freeze-drying lactobacillus of fungi preservation, it is 36 months that storage life, which is fixed tentatively,.
1.2 MEVB plants of Mink Parvovirus should meet following standard
1.2.1 seed culture of viruses cell maintenance medium work is serially diluted for 10 times by viral level, takes 10-4、10-5、10-6、10-7Four
Dilution, each dilution are inoculated with 4 holes, and every hole 0.1ml supplements CRFK cell suspension 0.9ml, set 37 DEG C and cultivate and observe 3~4
Day, calculate TCID50, every ml viral level answers >=106.50TCID50。。
1.2.2 erythrocyte agglutination valence is carried out according to note 3.1, and seed culture of viruses answers >=1:64 to swine erythrocyte agglutination titer.
1.2.3 virulence seed culture of viruses takes orally 2~10 monthly age health mink 5, every 15ml, observes 10,4 or more minks
Occur classical symptom (see note 1).
1.2.4 vaccine (inactivation provirus content >=10 are made according to this regulation in immunogenicity6.00TCID50) after, muscle connects
Kind 2~10 monthly age health mink 5, every 1ml, together with the identical control group mink of condition 5, oral challenge mink after 21 days
SMPV-11 plants of parvovirus (enteron aisle poison) 10ml (contains 100 ID50), it observes 10, immune mink should all be protected, right
It all falls ill according to mink, classical symptom occurs.
1.2.5 specific 1: 100 diluted seed culture of viruses and 1: 10 times of diluted Mink Parvovirus specific serum equivalent are mixed
It closes, after 37 DEG C neutralize 1 hour, is inoculated with 4 hole of CRFK cell, while setting 4 hole of virus control group, culture observation 4 days, test group should not
There is CPE, CPE should all occur in control group.
1.2.6 pure to test by existing " Chinese veterinary pharmacopoeia " annex, seed culture of viruses should be dirty without bacterium, mould, mycoplasma
Dye；Seed culture of viruses should be polluted without exogenous virus.
1.2.7 6~14 generation of algebra basic seed.
1.2.8 basic virus seed conservation cell culture wet poison -70 DEG C of storage lives of kind are 3 years；Vacuum freeze drying is placed on-
In 70 DEG C, storage life is 5 years.
1.2.9 virulent standard is examined
1.2.9.1 to the median infective dose (ID of mink50) SMPV-11 plants of internal organs poison of Mink Parvovirus are taken, use physiology salt
Water is made 10% emulsion, and multigelation twice and filters, every milliliter of 2000 unit of addition penicillin of filtrate, streptomycin sulphate
2000 μ g are placed in 4 DEG C of effects overnight, as the virulent stoste of inspection；Stoste carries out 10 times with physiological saline and is serially diluted, and takes original
Liquid, 10-1、10-2、10-3Four dilutions, each dilution gavage 3~10 monthly age health mink 4, every 10ml, observation 10
Day, calculate ID50, SMPV-11 strain virus is that every 10ml stoste answers >=100 ID to mink median infective dose standard50。
1.2.9.2 it examines with 100 ID of virulent virulence standard50SMPV-11 plants of internal organs poison of Mink Parvovirus gavage 3
~10 monthly age health minks 4,3~5d mink all falls ill after attacking poison, classical symptom occurs, virus is red to pig in mink excrement
Blood cell HA potency answers >=1: 256.
1.2.10 exogenous virus is examined is carried out by note 2.2, and seed culture of viruses should be polluted without exogenous virus.
1.2.11 it examines and uses 4~6 generation of generation with virulent.
1.2.12 examining with virulent virus seed conservation internal organs seed culture of viruses is 4 years in -70 DEG C of storage lives.
2 vaccine preparations and the inspection of semifinished product
2.1 mink hemorrhagic pneumonia inactivated vaccines
2.1.1 production is prepared with seed
2.1.1.1 first order seed breeding takes DL15 plants, JL08 plants, WD01 plants, WF05 plants, DL03 plants of bacterial strains jellies with identification
Each 1 unpacking of dry strain, is diluted with sterile saline, is inoculated with PYG agar medium respectively, and 36~37 DEG C of cultures 18~24 are small
When, 5 or more colonies typicals are selected respectively and are mixed in a small amount of PYG fluid nutrient medium, then are inoculated with the culture of PYG agar slant respectively
Base is several, and 36~37 DEG C are cultivated 18~24 hours, as first order seed.2~8 DEG C of preservations, validity period are no more than 15, and passage is not
More than 5 generations.
2.1.1.2 secondary seed breeding takes first order seed to be inoculated in several 5mlPYG fluid nutrient mediums respectively, and 36~37
It DEG C shaking 12 hours, then is inoculated in larger amount of PYG fluid nutrient medium respectively in 3% ratio, 36~37 DEG C shake 12 hours, warp
Purely after the assay was approved, as secondary seed, 2~8 DEG C of preservations are set, should be no more than 4.
2.1.2 seedling culture medium PYG improved culture medium.
2.1.2.1 seedling is prepared with bacterium solution
Fermentation seed liquid preparation: the 2.1.1.2 secondary seed is inoculated in fermentation medium, in temperature 37~37.5
DEG C, fermented and cultured 7h under the conditions of 100~120r/min of mixing speed, 70~90L/min of charge flow rate, 30~70Kpa of pressure, obtain
Obtain fermentation seed liquid；
One grade fermemtation: being inoculated in the 500L fermentor equipped with 250~300L culture medium in 3% ratio for fermentation seed liquid,
Defoaming agent GPE is added, glucose is added to final concentration of 1% and urea to final concentration of 2g/L as supplement after cultivating 6~7h
Carbon source, main control parameters are as follows during fermentation:: 37~37.5 DEG C of tank temperature, 80~110r/min of mixing speed, charge flow rate 80
~120L/min, tank press 30~70Kpa, 12h harvest, through purely after the assay was approved, as semi-finished product bacterium solution, bacterium number are stablized
25000000000 CFU/ml.
Second order fermentation: fermentation seed liquid is inoculated in the fermentation of the 1000L equipped with 500L~600L culture medium in 4% ratio
Tank, 6~7h of culture are added glucose to final concentration of 1% and urea to final concentration of 2g/L as supplementary carbon source, defoaming are added
Agent GPE, main control parameters are as follows during fermentation:: 37~37.5 DEG C of tank temperature, 80~100r/min of mixing speed, charge flow rate
90~136L/min, tank press 30~70Kpa, 12h harvest, through purely after the assay was approved, as semi-finished product bacterium solution, bacterium number can be stablized
In 25,000,000,000 CFU/ml.
2.1.3 it purely examines and tests by existing " Chinese veterinary pharmacopoeia " annex, it should be pure.
2.1.4 count plate carries out count plate by existing " Chinese veterinary pharmacopoeia " annex with PYG agar plate；Every milliliter
Bacterium number is not less than 2 × 1010CFU。
2.1.5 it inactivates and is slowly added to formalin by the 0.2% of bacterium solution total amount, stirring while adding, 36~37 DEG C of stirrings are gone out
It is 24 hours living.
2.1.3 the inspection of semifinished product
2.1.3.1 steriling test is tested by existing " Chinese veterinary pharmacopoeia " annex, answers asepsis growth.
2.1.3.2 inactivation is examined and is tested by existing " Chinese veterinary pharmacopoeia " annex, answers asepsis growth.
2.1.4 with seedling by steriling test and inactivation G type after the assay was approved, Type B, c-type, I type, F type bacterium solution according to 1:1:
1:1:1 (V/V) mixing is mink hemorrhagic pneumonia vaccine pentavalent seedling semi-finished product bacterium solution, every plant of bacterium after mixing after mixing well
Bacterium number be at least 4,000,000,000 CFU/mL.
Mink Parvovirus Enteritis inactivated vaccine:
2.2 Mink Parvovirus Enteritis inactivated vaccines
2.2.1 the production preparation of seed culture of viruses
2.2.1.1 seed culture of viruses breeding is suitably diluted basic seed culture of viruses with cell maintenance medium, is synchronized and is connect in 2% ratio
Kind is set 37 DEG C and is cultivated 3~4, when typical case CPE occurs in 80% or more cell, can harvest, -20 DEG C in CRFK cell suspension
It saves, indicates harvest date, seed culture of viruses algebra, loading amount etc..
2.2.1.2 virus seed identification should meet regulation by 1.2.1~1.2.6 progress.
2.2.1.3 it is no more than 12 months for -20 DEG C of virus seed conservation.
2.2.1.4 virus seed subculture was no more than for 4 generations.
2.2.2 the preparation of seedling virus liquid
2.2.2.1 the preparation of cat kidney passage cell (CRFK plants) prepares CRFK cell according to a conventional method.CRFK cell should accord with
Close following standard: cell should be without bacterium, mould and mycoplasma contamination；Cell rotates culture in MEM nutrient solution under the conditions of 37 DEG C,
Fine and close single layer should be formed in 36 hours；Cell base algebra was 43~48 generations, was no more than for 10 generations using generation.For production of vaccine
With.
2.2.2.2 seed culture of viruses will be produced by, which being inoculated with, is inoculated in the cat kidney passage cell suspension turn prepared in 1~2% ratio
In bottle.
2.2.2.3 rotating and culturing under the conditions of cell suspension is uniformly mixed 37 DEG C of postposition with seed culture of viruses with observation by culture, continuously
Observation 4 days, the cell of waste pollution or growth failure.
2.2.2.4 harvesting can harvest when CPE occurs in 70% or more cell, set -20 DEG C and freeze, then receive after melting
Cell culture is obtained in sterilization container, several bottles are 1 group, are frozen at -20 DEG C or less spare.
2.2.2.5 the inspection of seedling virus liquid carries out virus liquid viral level survey by 1.2.1.1,1.2.1.6 methods
Fixed and steriling test, every milliliter of viral level answer >=106.00TCID50, virus liquid should be without bacterium, mould contamination；If virus liquid is sick
Malicious content is 105.50~106.00TCID50Between, 5 times of concentrations are carried out by ultrafiltration, until meeting regulation.
It is molten by 0.2% addition formaldehyde of virus liquid total amount after filtering after 2.3 inactivate the virus liquid thawing that will examine qualification
Liquid, it is stirring while adding, it mixes well, sets and inactivated 24 hours at 37 DEG C, should be stirred continuously during inactivation.
2.4 the inspection of semifinished product
2.4.1 steriling test is separately sampled as unit of group by the virus liquid of harvest, by existing " Chinese veterinary pharmacopoeia " annex
It carries out, it should be without bacterium, fungus growth.
2.4.2 inactivation is examined to take to inactivate after liquid makees 1: 5 dilution is inoculated with 4 bottles of 5mlCRFK cell suspension, every bottle respectively
0.4ml sets and cultivates at 37 DEG C, changes liquid within 24 hours, passes for 1 generation after continuing culture 3 again, and lesion, harvest culture should not occur in cell
Negative, judgement inactivation qualification is presented in liquid hemagglutination test.
The preparation and packing of 3 Combined vaccines
Pseudomonas aeruginosa pentavalent seedling semi-finished product bacterium solution after qualified inactivation will be examined to press with parvovirus semi-finished product bacterium solution
The ratio of 2:1 (V/V) mixes, then mixed liquor and 40% (w/v, in terms of g/mL) aluminium hydroxide gel are mixed by 6:1 ratio uniform,
After mixing well, quantitative separating seals bottleneck.
1 Combined vaccine of table configuration component ratio is groped
It chooses PA vaccine G type progress vaccine formulation ratio to grope, according to production of vaccine content standard, sets containing for Combined vaccine
Amount: PA G type is 4,000,000,000 CFU/ml, and the content of parvovirus is 106.00TCID50, 4 groups are carried out to vaccine on the basis of this concentration
The mixing of different proportion (V/V), later intramuscular injection are immunized mink, 5/group, measure different groups of immune PAs of the mink after 28 days
ELISA value and MEV HI value, the results showed that, it is optimum proportioning that antibody is relatively high when C group PA:MEV=2:1, it is thus determined that
The PA:MEV configuration proportion of Combined vaccine is 2:1.
4 product inspections
After 4.1 characters are stood, upper layer is khaki clear liquid, and lower layer is pale precipitation, in uniformly mixed after shaking
Suspension.
4.2 steriling tests are tested by existing " Chinese veterinary pharmacopoeia " annex, equal asepsis growth.
Susceptible mink 5 of 2~10 monthly ages health of 4.3 safety verifications, each hind leg inside muscle vaccine inoculation 3ml (divide 3
Point injection, every 1.0ml), it is observed continuously 15.
4.4 efficacy test
4.4.1 mink hemorrhagic pneumonia efficacy test
4.4.1.1 mouse is divided into 5 groups, every group 10, bigeminy epidemic disease is subcutaneously injected respectively with 16~18g of weight mouse 50
Seedling 0.2ml divides 5 groups, every group 10, every group is subcutaneously injected 70,000,000 CFU/0.2ml respectively together with control mice 50 after 21 days
DL15 strain, WD01 plants or WF05 plants virulent liquid or 1.2 hundred million CFU/0.2ml JL08 strain or DL03 plants of virulent liquid, continuously
Observation 7 days.Control mice should be all dead, and immune mouse should at least protect 8.
4.4.1.2 susceptible mink 25 of 2~10 monthly ages health of mink divides 5 groups, every group 5, distinguishes intramuscular injection two
Vaccines 1ml divides 5 groups, every group 5, every group intratracheally instills 200,000,000 CFU/ml's respectively together with control mink 25 after 21 days
The JL08 strain of DL15 plants, WD01 plants or WF05 plants virulent liquid or 400,000,000 CFU/ml or DL03 plants of virulent liquid, are observed continuously 7.It is right
Should be all dead according to mink, immune mink should at least protect 4.
4.4.1.3 ELISA
Establish the ELISA method for mink hemorrhagic pneumonia, antibody yin and yang attribute critical value OD450It indicates, G type
DL15 plants, JL08 plants of Type B, WD01 plants of c-type, WF05 plants of I type, the critical value of DL03 plants of F type be set as 0.3100, OD value and be greater than
Critical value is then judged to the positive；Conversely, being then determined as feminine gender.With ELISA method monitoring Combined vaccine it is immune after pseudomonas aeruginosa G,
B, the variation of C, I, F type antibody, 0,7,14,21,28,60,90 after each group is inoculated with ELISA method measurement respectively after being immunized,
The green pseudomonad antibody level of 120,180 Copper in Serum.
4.4.2 Canine Parvovirus Enteritis efficacy test
4.4.2.1 serum antibody measurement susceptible mink (antibody titer≤1 Mink Parvovirus HI of 2~10 monthly ages health
: 4) it 5, each intramuscular inoculation vaccine 1ml, after 21 days, together with control mink 5, takes a blood sample respectively, measures HI and SN antibody titer,
Immune group mink antibody titer should all >=1: 32, control group mink antibody titer should all≤1: 4.
4.4.2.2 Immunization susceptible mink (antibody titer≤1 Mink Parvovirus HI: 4) 5 of 2~10 monthly ages health
Only, each intramuscular inoculation vaccine 1ml, it is each to take orally 100 ID together with control mink 5 after 21 days50Mink Parvovirus SMPV-
11 plants of internal organs poison are observed 9, and control group mink should all fall ill, and immune mink should all be good for work.
4.4.3 residual formaldehyde measurement is measured by existing " Chinese veterinary pharmacopoeia " annex respectively, should meet regulation.
5 effects are with purposes for preventing Mink Parvovirus Enteritis and by G type, Type B, c-type, F type, the false list of I type verdigris
The microbial mink hemorrhagic pneumonia of born of the same parents.Duration of immunity is 5 months.
Intramuscular injection on the inside of 6 usage and dosage hind legs.Every inoculation 1ml of mink.Intramuscular injection, 50~70 days after birth
The young ermine in age is inoculated with simultaneously with female ermine, and kind ermine breeds first 30~60 days and is inoculated with, every 1ml.
2 safety testing of embodiment
The 2 safety testing scope of examination of table
1.1 safety testing
201501, the single dose inoculation of 201502,201,503 3 batches of vaccines, the inoculation of single dose repeated inoculation, overdose
Different days mink carries out safety evaluatio, and a single dose is inoculated with 60~70 age in days children ermines, and 1ml/ is only；Single dose repeated inoculation
60~70 age in days children ermines, 2 inoculations midfeather 15 days are inoculated with 1ml/ only every time；Overdose be inoculated with 60~70 age in days children ermines and
The 3-6 monthly age is bred as ermine, and 3ml/ only, divides 3 points of injections.Every group of inoculation mink 5, hind leg inside intramuscular inoculation, and set up rather
Epidemic disease control group.It is observed continuously after inoculation 15, observation whole body clinical symptom and inoculation localized variation, and first 10 days after inoculation,
The daily morning records Temperature changing.
1.2 safety testing results:
201501, mink does not occur locally and systemically adverse reaction after 201502,201,503 3 batches of vaccine immunities, essence
Mind, appetite, body temperature and excrement variation without exception.Mink body temperature is identical as basal body temperature after inoculation, is kept at 38.6~41.5
Between DEG C, injection site is without enlargement after all inoculation mink inoculations, and without festering, young ermine upgrowth situation is good.Illustrate the vaccine
It is safer to mink.
3 Mink Parvovirus Enteritis of table, hemorrhagic pneumonia bivalent inactivated vaccine mink safety testing result
The effect evaluation of 3 MEV-PA bivalent inactivated vaccine of embodiment
One, the potency test of MEV-PA bivalent inactivated vaccine
1 immune grouping
1.1 mink
Take the 3 monthly ages susceptible mink 120 of health (the susceptible mink standard of health: Mink Parvovirus Serum HI antibody potency
≤ 1: 4, pseudomonas aeruginosa G, B, C, I, F mink serum macroscopic agglutination is feminine gender) 4 groups are randomly divided into, every group 40, divide
For MEV-PA group, MEV group, PA group and control group, muscle vaccinates 1ml/ only on the inside of hind leg respectively, control group the same manner note
Penetrate isometric physiological saline.
1.2 mouse
With 16~18g of weight mouse 50, it is divided into 5 groups, every group 10, vaccine 0.2ml is subcutaneously injected respectively.
2 mink hemorrhagic pneumonia Efficacy evaluations
2.1 mink
2.1.1 attacking malicious protection
Take 30 it is immune after 21 days, together with control mink 30, points 6 groups, every group 5 are immune and control group mink exists respectively
PADL15 plants malicious, JL08 plants, WD01 plants, WF05 plants, DL03 plants of bacterial strains and SMPV-11 plants of MEV are attacked within 21st, 90,180 after immune,
Each strain attacks 5 minks, observes 7, records death toll, and malicious protecting effect is attacked in measurement.
2.1.2 antibody determination
The 5 mink blood sample detection PA's of every group of acquisition on the 0th, 7,14,21,28,60,90,120,180 is anti-after immune
G, B, C, I, F type ELISA antibody.
2.2 mouse
21 days after 50 mouse immunes, together with control mice 50, divide 5 groups, every group 10, every group is subcutaneously injected respectively
The DL15 strain of 70000000 CFU/0.2ml, WD01 plants or WF05 plants virulent liquid or 1.2 hundred million CFU/0.2ml JL08 strain or DL03
The virulent liquid of strain, is observed continuously 7, records death toll.
3 Mink Parvovirus Enteritis Efficacy evaluations
3,1 antibody determination
5 mink blood sample detections of every group of acquisition on the 0th, 7,14,21,28,60,90,120,180 after vaccine immunity
SN the and HI antibody of MEV.
3.2 attack malicious protection
Above-mentioned immune and control group mink attacks poison 1 PADL15 plants of MLD, JL08 on the 21st, 90,180 after immune respectively
Strain, WD01 plants, WF05 plants, DL03 plants of bacterial strains and 100 ID50SMPV-11 plants of internal organs poison of Mink Parvovirus, each strain attack 5
Mink is observed 7, and death toll is recorded, and malicious protecting effect is attacked in measurement.
Two, the effect evaluation result of MEV-PA bigeminy vaccine:
1 mink hemorrhagic pneumonia efficacy test results
1.1 measurement results show that each serotype antibody turns sun from 7 days antibody, and highest on the 21st continues to 180d.With list
Seedling control is compared, and the antibody level difference for joining each serotype in seedling is not significant (P > 0.005).
1.1 attack malicious protection
1.1.1 mink MEV-PA Combined vaccine and the mono- seedling of PA are immunized after mink 30,90,180 respectively, together with control group, divide
DL15 plants of malicious PAG type is not attacked, and JL08 plants of Type B, WD01 plants of c-type, WF05 plants of I type, DL03 plants of F type, every kind of serotype and control are attacked
Poison group 5/group of random selection.Poison is attacked the result shows that 180 days, each group protects number 4/5 or more, and control group equal 100% is dead,
Vaccine protecting effect is preferable, and duration of immunity was up to 180 days.Compared with the mono- seedling of PA, the protecting effect of vaccine without significant difference (P >
0.005)。
1.1.2 mouse MEV-PA Combined vaccine and the mono- seedling of PA attack poison on the 21st the result shows that PA MEV-PA after mouse is immunized respectively
Mouse is immunized to DL15 plants of G type, JL08 plants of Type B in Combined vaccine and the mono- seedling of PA, and WD01 plants of c-type, WF05 plants of I type, DL03 plants of F type are attacked
Malicious protective rate is 100% (10/10).
2 Mink Parvovirus Enteritis efficacy tests
The measurement of 2.1 serum antibodies
Hemagglutination inhibition antibody (HI) uses HI method detection Combined vaccine and MEV seedling to be immunized the 0th, 7,14,21 after mink respectively,
Anti- MEV antibody after MEV HI antibody level in mink serum on the 28th, 60,90,120,180, Combined vaccine and MEV seedling are immune the
Antibody average value >=2 on the 7th5.9, continue within 28th~60 compared with High antibody level, be 29.5~210.4, until antibody on the 180th is higher,
It is 28~28.6.From graphical trend, compared with the immune rear level of the mono- seedling of MEV, MEV antibody is integrally relatively low after Combined vaccine is immune,
But otherness is not significant (P > 0.05).
2.2 neutralizing antibodies (SN) detect Combined vaccine with endpoint titration respectively and MEV seedling is immunized the 0th, 7,14 after mink,
Anti- MEV after anti-MEV SN antibody level in mink serum on the 21st, 28,60,90,120,180, Combined vaccine and MEV seedling are immune is anti-
Body antibody average value >=10 on the 7th0.8, continue within 28th~60 compared with High antibody level, be 101~101.29, until antibody on the 180th is equal
It is higher, it is 100.9.Compared with the immune rear level of the mono- seedling of MEV, MEV antibody is integrally relatively low after Combined vaccine is immune, but otherness is not shown
It writes (P > 0.05).
2.3 attack malicious MEV-PA Combined vaccine and the mono- seedling of MEV is immunized after mink 30,90,180 respectively, every group of random selection 5
Only, each to take orally 100 ID together with control 550SMPV-11 plants of internal organs poison of Mink Parvovirus.Poison is attacked the result shows that 180
Day, it is 5/5 that each group, which protects number, equal 5/5 morbidity of control group, it was demonstrated that vaccine protecting effect is preferable, and duration of immunity was up to 180 days.With
The mono- seedling of MEV is compared, and the protecting effect difference of Combined vaccine is not significant (P > 0.05).
4 Combined vaccine of table is immunized mink and attacks poison protection result
5 Combined vaccine of table is immunized mouse and attacks within 21st poison protection result
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of P. aeruginosa bacterial strain, which is characterized in that its deposit number is CGMCC No.11990.
2. application of the P. aeruginosa bacterial strain according to claim 1 in preparation mink hemorrhagic pneumonia vaccine.
3. P. aeruginosa bacterial strain according to claim 1 is preparing Mink Parvovirus Enteritis, hemorrhagic pneumonia two
Join the application in inactivated vaccine.
4. a kind of mink hemorrhagic pneumonia vaccine, which is characterized in that by P. aeruginosa bacterial strain described in claim 1 and water
DL15 plants of ermine pseudomonas aeruginosa G type, JL08 plants of Type B be made.
5. the bivalent inactivated vaccine of a kind of Mink Parvovirus Enteritis, hemorrhagic pneumonia, which is characterized in that by claim 1
The P. aeruginosa bacterial strain and DL15 plants of mink pseudomonas aeruginosa G type, JL08 plants of Type B and Mink Parvovirus strain
MEVB plants are made.
6. the preparation method of bivalent inactivated vaccine according to claim 5, which comprises the steps of:
Step 1: taking P. aeruginosa bacterial strain and DL15 plants of mink pseudomonas aeruginosa G type, Type B described in claim 1
JL08 plants are inoculated in mixing after culture medium culture respectively, pseudomonas aeruginosa pentavalent seedling semi-finished product bacterium after inactivation are made after inactivation
Liquid；
Step 2: taking MEVB plants of inoculating cells of Mink Parvovirus strain, harvest inactivates obtained parvovirus semi-finished product；
Step 3: taking pseudomonas aeruginosa pentavalent seedling semi-finished product bacterium solution and tiny disease made from step 2 after step 1 inactivation obtained
Malicious semi-finished product are mixed to prepare mixed liquor；
Step 4: mixed liquor made from step 3 being taken to mix with adjuvant.
7. preparation method according to claim 6, which is characterized in that P. aeruginosa described in claim 1 in step 1
Bacterial strain and DL15 plants of mink pseudomonas aeruginosa G type, JL08 plants of Type B are respectively after culture medium culture, the mixed ratio
For 1:1:1:1:1, the bacterium number of every plant of bacterium is at least 4,000,000,000 CFU/mL after mixing.
8. preparation method according to claim 6 or 7, which is characterized in that parvovirus in step 2 parvovirus semi-finished product
Content be 106.00TCID50。
9. according to the described in any item preparation methods of claim 6 to 8, which is characterized in that go out made from step 1 described in step 3
The ratio of the mixing of parvovirus semi-finished product made from pseudomonas aeruginosa pentavalent seedling semi-finished product bacterium solution and step 2 is 2:1 after work.
10. according to the described in any item preparation methods of claim 6 to 9, which is characterized in that culture medium described in step 1 is in PYG
MgSO is added in culture medium4, sodium citrate, vitamin, urea, Na2HPO4Buffer salt or KH2PO4One of buffer salt is more
Kind；
Inoculation described in step 1 is according to 3% inoculating strain of PYG culture volume；Inoculation described in step 2 is thin according to CRFK
Inactivation described in the 2% virus inoculation step 1 or step 2 of born of the same parents' suspension volume uses formalin-inactivated；The dosage of the formaldehyde is bacterium solution
The 0.2% of total amount；
Adjuvant described in step 4 is 40% (w/v, in terms of g/mL) aluminium hydroxide gel, mixed liquor made from step 3 and the adjuvant
Mixed proportion is 6:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910118327.1A CN109652344A (en) | 2016-02-17 | 2016-02-17 | Bacterial strain and its application and vaccine and preparation method thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610089542.XA CN105713855A (en) | 2016-02-17 | 2016-02-17 | Strains, application of strains, vaccine and preparation method of vaccine |
| CN201910118327.1A CN109652344A (en) | 2016-02-17 | 2016-02-17 | Bacterial strain and its application and vaccine and preparation method thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610089542.XA Division CN105713855A (en) | 2016-02-17 | 2016-02-17 | Strains, application of strains, vaccine and preparation method of vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109652344A true CN109652344A (en) | 2019-04-19 |
Family
ID=56155792
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910117023.3A Pending CN109929776A (en) | 2016-02-17 | 2016-02-17 | Bacterial strain and its application and vaccine and preparation method thereof |
| CN201910118327.1A Pending CN109652344A (en) | 2016-02-17 | 2016-02-17 | Bacterial strain and its application and vaccine and preparation method thereof |
| CN201610089542.XA Pending CN105713855A (en) | 2016-02-17 | 2016-02-17 | Strains, application of strains, vaccine and preparation method of vaccine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910117023.3A Pending CN109929776A (en) | 2016-02-17 | 2016-02-17 | Bacterial strain and its application and vaccine and preparation method thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610089542.XA Pending CN105713855A (en) | 2016-02-17 | 2016-02-17 | Strains, application of strains, vaccine and preparation method of vaccine |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN109929776A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106390111A (en) * | 2016-11-25 | 2017-02-15 | 于彦强 | Preparation method of mink hemorrhagic pneumonia inactivated vaccine and application thereof |
| CN107881154B (en) * | 2017-12-26 | 2021-03-05 | 中国农业科学院特产研究所 | Raccoon parvovirus attenuated vaccine strain and application thereof in preparation of raccoon parvovirus attenuated vaccine |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000327A (en) * | 2010-12-01 | 2011-04-06 | 齐鲁动物保健品有限公司 | Mink viral enteritis inactivated vaccine and preparation method thereof |
| CN102286391A (en) * | 2010-06-21 | 2011-12-21 | 中国农业科学院特产研究所 | Mink hemorrhagic pneumonia divalent inactivated vaccine and preparation method threof |
| CN103948918A (en) * | 2014-03-21 | 2014-07-30 | 母连志 | Method for preparing trivalent inactivated vaccine for preventing mink hemorrhagic pneumonia |
| CN104383530A (en) * | 2014-10-22 | 2015-03-04 | 中国农业科学院特产研究所 | Mink canine distemper-parvovirus enteritis bigeminal live vaccine as well as preparation method and application thereof |
| CN104388394A (en) * | 2014-10-22 | 2015-03-04 | 中国农业科学院特产研究所 | Mink parvovirus attenuated vaccine strain and application of mink parvovirus attenuated vaccine strain in preparation of mink parvovirus attenuated vaccine |
| CN104587460A (en) * | 2014-12-25 | 2015-05-06 | 华威特（北京）生物科技有限公司 | Mink viral enteritis and canine distemper binary living vaccine as well as preparation method and application thereof |
| CN105031639A (en) * | 2015-07-09 | 2015-11-11 | 吉林特研生物技术有限责任公司 | Mink distemper-canine parvovirus enteritis bivalent vaccine and its preparation method and use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5296729A (en) * | 1976-02-05 | 1977-08-13 | Shionogi & Co Ltd | Mixed vaccin for cyanomycosis |
-
2016
- 2016-02-17 CN CN201910117023.3A patent/CN109929776A/en active Pending
- 2016-02-17 CN CN201910118327.1A patent/CN109652344A/en active Pending
- 2016-02-17 CN CN201610089542.XA patent/CN105713855A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102286391A (en) * | 2010-06-21 | 2011-12-21 | 中国农业科学院特产研究所 | Mink hemorrhagic pneumonia divalent inactivated vaccine and preparation method threof |
| CN102000327A (en) * | 2010-12-01 | 2011-04-06 | 齐鲁动物保健品有限公司 | Mink viral enteritis inactivated vaccine and preparation method thereof |
| CN103948918A (en) * | 2014-03-21 | 2014-07-30 | 母连志 | Method for preparing trivalent inactivated vaccine for preventing mink hemorrhagic pneumonia |
| CN104383530A (en) * | 2014-10-22 | 2015-03-04 | 中国农业科学院特产研究所 | Mink canine distemper-parvovirus enteritis bigeminal live vaccine as well as preparation method and application thereof |
| CN104388394A (en) * | 2014-10-22 | 2015-03-04 | 中国农业科学院特产研究所 | Mink parvovirus attenuated vaccine strain and application of mink parvovirus attenuated vaccine strain in preparation of mink parvovirus attenuated vaccine |
| CN104587460A (en) * | 2014-12-25 | 2015-05-06 | 华威特（北京）生物科技有限公司 | Mink viral enteritis and canine distemper binary living vaccine as well as preparation method and application thereof |
| CN105031639A (en) * | 2015-07-09 | 2015-11-11 | 吉林特研生物技术有限责任公司 | Mink distemper-canine parvovirus enteritis bivalent vaccine and its preparation method and use |
Non-Patent Citations (8)
| Title |
|---|
| 杨婕妤等: "绿脓杆菌多价灭活疫苗效价跟踪及初步免疫效果观察", 《黑龙江畜牧兽医》 * |
| 柴秀丽等: "水貂细小病毒性肠炎灭活疫苗保存期试验", 《经济动物学报》 * |
| 王海洲: "水貂出血性肺炎的诊断和治疗", 《特种经济动植物》 * |
| 王海洲: "水貂出血性肺炎的诊治二例", 《北方牧业》 * |
| 白雪等: "水貂出血性肺炎流行病学调查及绿脓杆菌疫苗研究进展", 《现代农业科技》 * |
| 郭玉广等: "一例由绿脓杆菌引起的水貂出血性肺炎的诊治", 《中国动物检疫》 * |
| 闫喜军等: "水貂出血性肺炎多价灭活疫苗研制成功", 《特产研究》 * |
| 韩明明: "绿脓杆菌比色LAMP检测法的建立及水貂出血性肺炎绿脓杆菌三价灭活疫苗的研制", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105713855A (en) | 2016-06-29 |
| CN109929776A (en) | 2019-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258776B (en) | Combined inactivated vaccine against mycoplasma hyopneumoniae (MHP) and mycoplasma hyorhinis and preparation method thereof | |
| CN103182076B (en) | Swine mycoplasma pneumoniae inactivated vaccine and preparation method thereof | |
| CN101612396B (en) | Canine distemper live vaccine and preparation method thereof | |
| CN108904796A (en) | Rabbit hemorrhagic disease virus baculovirus vector, pasteurella multocida disease bivalent inactivated vaccine and preparation method thereof | |
| CN105031639A (en) | Mink distemper-canine parvovirus enteritis bivalent vaccine and its preparation method and use | |
| CN103436583A (en) | Method for producing therapeutic monoclonal antibody of canine distemper virus, product thereof and hybridoma cell | |
| CN104258386B (en) | A kind of mink viral enteritis inactivated vaccine-canine distemper live vaccine combination | |
| CN103160555A (en) | Culture medium, culture method and application of high-yield exotoxin of clostridium perfringens | |
| CN104087559B (en) | A kind of infectious bursa of Fabricius virus, inactivated vaccine and preparation method thereof | |
| CN106834168B (en) | A kind of streptococcus suis 2-type low virulent strain and its application | |
| CN109652344A (en) | Bacterial strain and its application and vaccine and preparation method thereof | |
| CN108143764A (en) | The preparation method that a kind of four gentleman of composite bacteria fermentation dissipate | |
| CN101766814A (en) | Swine pasteurellosis bivalent inactivated vaccine and preparation method thereof | |
| CN101745105B (en) | Inactivated vaccine for streptococcus suis and pasteurella multocida diseases and preparation method thereof | |
| CN104069489B (en) | Newcastle disease and infectious bursa of Fabricius bivalent inactivated vaccine and preparation method thereof | |
| CN110016457A (en) | The Rough Anti-Brucella and its immunogenic production process of one plant weight group Echinococcus Granulosus Cysts Eg95 gene | |
| CN109010814A (en) | The production method of haemophilus parasuis and mycoplasma hyopneumoniae bivalent inactivated vaccine | |
| CN105420153B (en) | A kind of Pseudomonas aeruginosa fermentation medium and its fermentation culture method, vaccine preparation method | |
| CN107338227A (en) | Bovine parainfluenza virus PBIV3 B strains and its application | |
| CN106520601A (en) | Streptococcus suis serotype 2 XD strain and application | |
| CN105749266A (en) | Mink hemorrhagic pneumonia and botulism combined inactivate vaccine and preparing method thereof | |
| CN102391975B (en) | Actinobacillus pleuropneumoniae serotype 2 bacterial strain and its preparation method | |
| CN103623400B (en) | Vaccine composition for resisting pig mycoplasma pneumonia and infectious pleuropneumonia and preparation method and preparation method | |
| CN110448690A (en) | A kind of infectious coryza of chicken (A type+Type B+c-type), nose tracheae ornithosis bacillosis (A type) bivalent inactivated vaccine | |
| CN104645324A (en) | Application of swine enzootic hyopneumoniae vaccine strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190419 |